INTRODUCTION AND OBJECTIVES: Microbes in the urine trigger immune responses similar to intravesical BCG, suggesting that common bacteria may also exert an antitumor effect.
METHODS: We investigated recurrence rates in 387 patients with low-grade, papillary non-invasive bladder tumors (TaLG), with or without asymptomatic bacteriuria (ABU). They were followed every 6 months for 36 months, and did not receive antibiotics or intravesical chemotherapy. Recurrent tumors were treated generally by outpatient fulguration. Before cystoscopy, patients submitted a voided urine sample for culture, stratified as no growth, <104, >104 or >105 CFU/ ml single organism. Any degree of bacteria on culture was classified as ABU. We also measured absolute neutrophil counts (ANC) and the presence of pyuria, as surrogate indicators of local immune response.
RESULTS: Of the 387 cases, 200 (52%) had ABU, including 102 (27%) with >104 CFU/ml bacteriuria. With absolute 3-year followup, 75% of patients with ABU survived tumor-free compared to 40% of 187 uninfected patients (P[.001). Sixty per cent of patients with negative cultures recurred versus 25%, 14%, and 29% of patients with <104, >104 or >105 CFU/ml. (P[.001). Mean number of recurrent tumors in colonized patients was 4.2 vs 8.4 in uninfected patients (P[.009). ANC averaged 6.3 K/mcL in bacteriuric vs. 4.1 K/ mcL in uninfected patients (P[.01).
CONCLUSIONS: Patients with papillary TaLG tumors and chronic asymptomatic bacteriuria had fewer recurrences, fewer numbers of recurrent tumors, and longer tumor-free survival times than similarly staged uninfected patients. Bladder-resident bacteria may reduce bladder tumor recurrences through local immune mechanisms.
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PD13-05 ANDROGEN SUPPRESSION THERAPY IS ASSOCIATED WITH LOWER RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER
Shuo-chieh Wu*, Felix V. Chen, Deukwoo Kwon, Maria C. Velasquez, Sanoj Punnen, Dipen J. Parekh, Chad R. Ritch, Mark L. Gonzalgo, Miami, FL INTRODUCTION AND OBJECTIVES: Despite major advancements in the multimodal management of bladder cancer (BC), treatment continues to be challenged by high rates of recurrence and disease progression. Clinical investigations have begun to explore the role of androgen suppression therapy (AST) as an adjunct to BC treatment. We present a single-institution analysis of the association between AST and BC recurrence and progression. METHODS: We included male patients with a diagnosis of nonmuscle invasive bladder cancer (NMIBC) from our institutional database. Patient charts were reviewed for history of AST. Subjects who started AST after documented recurrence and/or progression were excluded. BC was classified in accordance with AUA risk stratification guidelines. Hazard ratios (HR) were estimated with a Cox proportional hazards model. Kaplan-Meier analysis and log-rank test were used to compare recurrence-free survival (RFS) and progression-free survival (PFS) between groups.
RESULTS: A total of 274 males met inclusion criteria, including 36 with AST and 238 without AST. Median follow-up was 3.2 years. AST consisted of 5-alpha reductase inhibitor (n [ 26), gonadotropinreleasing hormone agonist (n [ 10), and antiandrogen (n [ 7). Six patients received more than one type of AST. Intravesical recurrence was observed in 47% and 71% of patients, and tumor progressed in 14% and 29% of patients with and without AST, respectively. AST was associated with a significantly lower risk of recurrence (HR 0.52, p [ 0.02) as well as improved RFS (p [ 0.014). However, no statistically significant reduction of progression (HR 0.61, p [ 0.35) or improvement of PFS (p [ 0.23) was observed with AST. After risk stratification, high-risk classification was found to be an independent predictor of recurrence (HR 1.55, p < 0.01) and progression (HR 3.38, p < 0.01). Notably, all 5 patients who progressed on AST had high-risk disease, whereas no patients with low/intermediate-risk disease progressed on AST.
CONCLUSIONS: In this retrospective, single-institution bladder cancer registry study, AST was associated with a lower risk of recurrence in NMIBC. Further investigation is warranted to define the role of AST as an adjunctive therapy for management of bladder cancer.
